The unit, located on the campus of AdventHealth Celebration, will offer investigational treatments to patients with solid tumors and blood cancers.

Moffitt Cancer Center and AdventHealth have opened the doors of their joint Clinical Research Unit at AdventHealth Celebration, a specialized facility for early drug development, clinical trials and research.

The facility has 28 chairs in the infusion center to provide standard therapies and 13 newly added chairs in the clinical research unit reserved for investigational therapies. Care will be provided to patients with solid tumors and blood cancers.

“The opening of this unit will allow patients in Central Florida to access the latest investigational therapies,” said Dr. George Simon, executive medical director of the joint clinical research unit and infusion center. “As we launch more trials, we plan to offer cutting edge anti-cancer treatments, including novel targeted therapies, monoclonal antibodies, antibody-drug conjugates and other therapeutic platforms.”

The unit’s opening is the latest step in the two major cancer providers’ partnership. The first collaborative clinical trial of the partnership – a Phase I trial testing the effectiveness of a promising new combination therapy for lung cancer – launched in September. Several other collaborative investigator-initated efforts are currently under development.

“At AdventHealth Celebration, we are combining our expertise and resources, providing even more Floridians with access to world-class cancer care close to home,” said Dr. Nikhil Khushalani, Assistant Center Director of Clinical Research Review and Partnerships and senior member of the Department of Cutaneous Oncology at Moffitt Cancer Center.